Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Account Payables: 2021-2024

Historic Change in Account Payables for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to -$19.1 million.

  • Amylyx Pharmaceuticals' Change in Account Payables rose 99.05% to -$33,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 137.38%. This contributed to the annual value of -$19.1 million for FY2024, which is 220.27% down from last year.
  • As of FY2024, Amylyx Pharmaceuticals' Change in Account Payables stood at -$19.1 million, which was down 220.27% from $15.9 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Change in Account Payables ranged from a high of $15.9 million in FY2023 and a low of -$19.1 million during FY2024.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Change in Account Payables value was $1.9 million (recorded in 2022), while the average stood at -$455,333.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Change in Account Payables surged by 756.63% in 2023, and later plummeted by 220.27% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Change in Account Payables (Yearly) stood at $670,000 in 2021, then soared by 176.72% to $1.9 million in 2022, then spiked by 756.63% to $15.9 million in 2023, then slumped by 220.27% to -$19.1 million in 2024.